MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (22)
2023
-
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
European Journal of Cancer, Vol. 184, pp. 48-59
2022
-
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634
-
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
npj Precision Oncology, Vol. 6, Núm. 1
2021
-
21-gene assay to inform chemotherapy benefit in node-positive breast cancer
New England Journal of Medicine, Vol. 385, Núm. 25, pp. 2336-2347
-
Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
European Journal of Cancer, Vol. 151, pp. 49-62
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 60-72
2019
-
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: Longitudinal analyses from the randomized phase III ExteNET trial
Annals of Oncology, Vol. 30, Núm. 4, pp. 567-574
-
IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer
Future Oncology, Vol. 15, Núm. 17, pp. 1951-1961
-
PIK3CA alterations and benefit with neratinib: Analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Breast Cancer Research, Vol. 21, Núm. 1
2017
-
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)
Annals of Oncology, Vol. 28, Núm. 2, pp. 313-320
-
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700
2016
-
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
European Journal of Cancer, Vol. 53, pp. 75-83
-
Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [Supportive Care in Cancer, (2015), DOI:10.1007/s00520-015-2904-5]
Supportive Care in Cancer
-
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 367-377
-
Phase 2 Study of Trabectedin in Patients With Hormone Receptor–Positive, HER-2–Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene
Clinical Breast Cancer, Vol. 16, Núm. 5, pp. 364-371
-
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 447-455
2014
-
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis
Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039
2011
-
Overview of preoperative radiochemotherapy in breast cancer: Past or future?
Clinical and Translational Oncology, Vol. 13, Núm. 7, pp. 446-450
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials
The Lancet, Vol. 378, Núm. 9793, pp. 771-784